A TQTc Study for Omaveloxolone

Inclusion Criteria: * Healthy adult males and/or females, 18 to 55 years of age (inclusive) at the time of screening. * BMI at screening between 18.0 and 32.0 kg/m2 (inclusive) * Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception. * Able to comprehend and willing to sign an ICF and to abide by the study restrictions. Exclusion Criteria: * History of clinically significant drug allergies, including allergies to any of the components of the study drugs (omaveloxolone and moxifloxacin) and/or clinically significant food allergies as determined by the investigator. * Subject has an ECG abnormality, including corrected QT interval (QTc)\> 450 msec for males, and \> 460 msec for females, HR \< 45 bpm or \> 100 bpm after 5 minutes in supine position, PR interval \> 220 msec, or QRS interval \> 110 msec. * Subject has allergy to band aids, adhesive dressing, or medical tape. * Subject has hypotension (systolic blood pressure blood pressure \[BP\] ≤ 90 mmHg, diastolic BP ≤ 50 mmHg), or hypertension (systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg) at screening. * Subject has history of prolonged QTc, cardiac arrhythmia, or first-degree relatives with congenital Long QT syndrome or unexplained sudden death in young age. * Subject has a history of unstable angina, syncope, coronary artery disease, myocardial infarction, congestive heart failure (CHF), transient ischemic attack (TIA), or neurological disorder. * Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator. * Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines. * Requirement for any over the counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis * Use of any medications (over the counter and/or prescription medication), vitamins, and/or herbal supplements, within the 14-days prior to study drug administration or within 5 halflives (if known), whichever is longer * History of drug or alcohol abuse in the last 6 months as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. * Positive test result for drugs of abuse, alcohol, or cotinine at screening or Day -1. * Positive test result for hepatitis B surface antigen, hepatitis C virus antibodies, or HIV antibodies at screening. * Positive test result for COVID-19 at Day -1. * Blood donation (excluding plasma donation) of approximately 500 mL within 56 days before screening or plasma donation within 7 days before screening. * Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days before study drug administration. * Consumption of alcohol within 72 hours before study drug administration. * Consumption of grapefruit, grapefruit products, star fruit, star fruit products, Seville oranges, or Seville orange products within the 72-hour period before study drug administration. * Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration. * Current enrollment in another clinical study. * Previous enrollment in any clinical study involving omaveloxolone.